Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Kathleen M. Dungan MD, MPH Advisory Board

Deborah J. Wexler MD, MSc Associate Editor

Silvio E. Inzucchi MD Editor-in-Chief

See All Experts

featured

Published in Diabetes and

Journal Scan / Research · September 08, 2021

Obesity and Effects of Dapagliflozin on Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes

European Heart Journal

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Ashish Aggarwal MD, FACC, FSCAI

João Ferreira MD, PhD

European Heart Journal

Obesity and Effects of Dapagliflozin on Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes Mellitus in the DECLARE-TIMI 58 Trial

Eur Heart J 2021 Aug 24;[EPub Ahead of Print], K Oyama, I Raz, A Cahn, J Kuder, SA Murphy, DL Bhatt, LA Leiter, DK McGuire, JPH Wilding, KS Park, A Goudev, R Diaz, J Špinar, IAM Gause-Nilsson, O Mosenzon, MS Sabatine, SD Wiviott

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Obesity, Metabolic Syndrome, and Prediabetes

Obesity and Effects of Dapagliflozin on Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes

Additional Info

Obesity and Effects of Dapagliflozin on Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes Mellitus in the DECLARE-TIMI 58 Trial

Further Reading

Glycemic Threshold Above Which Improvements in β-Cell Function and Glycemia in Response to Insulin Therapy Is Amplified in Individuals With Early Type 2 Diabetes

Racial and Ethnic Disparities in Early Glycemic Control Trends Among Veterans With Newly Diagnosed Type 2 Diabetes

Characterizing the Effects of Using GLP-1 Receptor–Based Agonists on Body Composition

Once-Weekly Semaglutide in Individuals With Obesity and Knee Osteoarthritis

Efficacy of Vitamin D Supplementation on Glycaemic Control in Individuals With Type 2 Diabetes

The SEAD Program Improved Clinical Outcomes in Underserved Young Adults With Type 1 Diabetes

Effects of Semaglutide Use on Obesity in Patients Undergoing Dialysis for Kidney Failure

Risk of Complications and Mortality Rates Among Individuals With Younger- vs Later-Onset Type 2 Diabetes

Regional Heterogeneity in the Efficacy of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes

Gastric Bypass Elicits Persistent Gut Adaptation and Unique Diabetes Remission–Related Metabolic Gene Regulation

Associations of Diabetes and Prediabetes With Mortality and Life Expectancy in Chinese Individuals

Recently Updated